$5,165.62 speaking Payment -- AbbVie Inc to Dr. Jessica Moore
AbbVie Inc. Compensates Gastroenterologist Dr. Jessica Moore for Speaking Engagement on Farxiga
This page provides a detailed analysis of a $5,165.62 speaking payment from AbbVie Inc to Dr. Jessica Moore. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $5,165.62 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | AbbVie Inc |
| Physician | Dr. Jessica Moore |
| NPI Number | 1765339350 |
| Physician Specialty | Gastroenterology |
| Location | Cambridge, MA |
| Date of Payment | 2025-11-07 |
| Related Drug/Device | Farxiga |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
AbbVie Inc made a $5.2K speaking payment to Jessica Moore, a Gastroenterology specialist in Cambridge, MA. The payment was associated with Farxiga. AbbVie Inc. paid Dr. Jessica Moore $5,165.62 on November 7, 2025, for speaking engagements related to Farxiga. The payment was for Dr. Moore's role as faculty or speaker, indicating her expertise in the subject matter. This payment falls under the 'speaking' category, which is a common form of engagement between pharmaceutical companies and healthcare professionals.
Patient Guidance: What This Payment Means for You
Patients should be aware that their doctors may receive payments from pharmaceutical companies for sharing their expertise on medications like Farxiga. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for speaking engagements are a common practice in the pharmaceutical industry, particularly for specialists like gastroenterologists who may be involved in educating peers about specific drugs or devices.
Regulatory Context: Sunshine Act Requirements
This payment is subject to reporting under the Sunshine Act (part of the Affordable Care Act), requiring disclosure of financial relationships between drug manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- speaking-engagements
- physician-compensation
- gastroenterology
- drug-marketing
- open-payments
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $5.2K payment for?
This was a speaking payment of $5.2K from AbbVie Inc to Jessica Moore, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Farxiga. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Jessica Moore accept pharmaceutical money?
Yes, Jessica Moore received this $5.2K payment from AbbVie Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Jessica Moore's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $5.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Gastroenterology?
To compare this payment against Gastroenterology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Gastroenterology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Jessica Moore's relationship with AbbVie Inc?
The payment amount of $5,165.62 is specific and documented. This $5.2K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Gastroenterology?
The payment date is set for November 7, 2025, in the future.
What should patients do after learning about this payment?
Patients should be aware that their doctors may receive payments from pharmaceutical companies for sharing their expertise on medications like Farxiga.
What else should I know about this speaking payment?
Dr. Moore's specialty is Gastroenterology, and the payment is linked to Farxiga.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.